Summary of Alpha Tau Conference Call Company Overview - **Company**: Alpha Tau Medical - **Product**: Alpha DaRT, a local intratumoral injection delivering alpha particle radiation directly into tumors, which is more efficient than traditional radiation therapies [2][3] Key Updates and Developments - **Transformative Year**: 2026 is expected to be a transformative year for Alpha Tau, with significant advancements in their clinical studies and regulatory approvals [2][15] - **FDA Programs**: Alpha Tau is part of the FDA's Total Product Lifecycle Advisory Program (TAP), which helps accelerate the commercial pathway for therapies [5] Clinical Trials and Data - **Pancreatic Cancer Study**: Data presented at the ASCO GI conference showed promising safety and disease control, with no significant immune suppression observed [6][8] - **FDA Submission**: A rolling submission for approval of Alpha DaRT in recurrent cutaneous squamous cell carcinoma (SCC) has begun, allowing for modular submissions to expedite the process [9][10] - **Japan Approval**: Alpha DaRT received approval in Japan for locally advanced unresectable and locally recurrent head and neck cancer, marking the first approval outside of Israel [11][12] - **Market Potential**: In the U.S., there are approximately 1.8 million new cutaneous SCC cases annually, with an estimated target market of 64,000 cases for Alpha DaRT [29][30] Market Strategy - **Focus on Difficult Cases**: Alpha Tau aims to target patients with difficult-to-treat cancers, particularly those with local recurrences or nodal spread [30] - **Partnerships**: The company is exploring partnerships for distribution and commercialization, particularly in Japan, and is open to collaborations on combination therapies with checkpoint inhibitors [38][39][42] Financial Position - **Cash Reserves**: Alpha Tau reported $77 million in cash and deposits at the end of the year, with a burn rate of $5-$6 million per quarter for operations [22][23] Future Outlook - **Upcoming Milestones**: Key studies in skin cancer, pancreatic cancer, and glioblastoma are expected to yield significant data in the second half of the year [17][21] - **Transformative Changes**: The company anticipates a substantial transformation by next year, driven by the outcomes of pivotal studies and potential new partnerships [48] Additional Considerations - **Regulatory Challenges**: Japan's regulatory environment is noted as challenging, but the approval is seen as a validation of Alpha DaRT's potential [11][12] - **Operational Stability**: Despite regional military actions, Alpha Tau has not experienced material disruptions to its operations [45] This summary encapsulates the key points from the conference call, highlighting Alpha Tau's innovative approach to cancer treatment, recent achievements, and strategic direction moving forward.

(NASDAQ:DRTS) Investor Presentation 1 Disclaimer This presentation (together with oral statements made in connection herewith, the "Presentation") is for informational purposes only to assist interested parties in making their own evaluation with respect to Alpha Tau Medical Ltd. ("Alpha Tau" or the "Company"). By accepting this Presentation, you acknowledge and agree that all of the information contained herein or disclosed orally during this Presentation is confidential, that you will not distribute, repr ...

Core Viewpoint - H.C. Wainwright analyst Yi Chen has raised the price target for Alpha Tau (DRTS) to $12 from $9, maintaining a Buy rating following Japan's Ministry of Health, Labour and Welfare granting marketing approval for Alpha DaRT to treat unresectable locally advanced or locally recurrent head and neck cancer [1] Group 1 - The approval in Japan validates the Alpha DaRT platform [1] - The approval helps to de-risk clinical development in the U.S. [1]

Core Insights - Alpha Tau Medical Ltd. has received regulatory marketing approval for its Alpha DaRT cancer therapy in Japan, marking the first approval outside of Israel [1][2][3] - The approval is a significant milestone for the company and reflects strong collaboration with Japanese regulators and clinical societies [1][3] Regulatory Approval - The Shonin approval process in Japan is known for its rigor, requiring a review by the Pharmaceuticals and Medical Devices Agency (PMDA) [2] - As part of the approval, Alpha Tau will conduct a post-market surveillance study involving 66 patients across five clinical centers in Japan to assess the safety and clinical performance of Alpha DaRT [2] Clinical Significance - The Alpha DaRT platform is designed to deliver intra-tumoral alpha-emitting radiotherapeutics, which has shown promise in treating unresectable locally advanced or locally recurrent head and neck cancer [1][7] - The therapy aims to provide a new treatment option for patients who have not responded to conventional therapies, potentially expanding the range of treatment options available [4][5] Collaboration and Future Plans - Alpha Tau plans to work closely with Japanese clinicians to complete the post-market surveillance study and generate high-quality clinical data [3] - The company anticipates discussions with the MHLW regarding potential reimbursement approaches for Alpha DaRT in Japan, aiming for broader clinical evaluation and potential studies for additional tumor types [3] Company Background - Alpha Tau Medical Ltd. was founded in 2016 and focuses on the research, development, and commercialization of Alpha DaRT for solid tumors [6] - The technology was developed by researchers from Tel Aviv University and aims to deliver targeted alpha-irradiation to tumors while sparing healthy tissue [7]

Core Insights - Alpha Tau Medical Ltd. is preparing for a highly active clinical year in 2026, with significant patient recruitment and data readouts expected from various cancer trials, including the ReSTART pivotal trial for skin cancer and studies for internal organ cancers [1][12] Clinical Trials and Developments - The company is conducting multiple significant clinical trials globally, with five approved trials in the U.S. and additional trials in France, Italy, and the UK, focusing on various cancer types [2][3] - Ongoing trials include treatments for prostate, lung, and pancreatic tumors, as well as a pivotal trial for recurrent cutaneous squamous cell carcinoma (cSCC) [3][5] - The company is targeting completion of patient recruitment for the pancreatic cancer study by the end of Q1 2026, with initial results expected by year-end [7] - Initial results from the glioblastoma multiforme (GBM) trial are anticipated around the end of Q4 2026, with a cautious approach to patient enrollment [8] Regulatory and Commercial Readiness - Alpha Tau is awaiting a response from Japan's Ministry of Health regarding approval for Alpha DaRT in treating recurrent head and neck cancer, which would mark its first commercial approval outside Israel [9] - The company is preparing for potential post-marketing surveillance in Japan and is also exploring a new clinical trial combining Alpha DaRT with checkpoint inhibitors for advanced head and neck cancer [10] - Manufacturing capabilities are being ramped up in Jerusalem and a new facility in New Hampshire, with a focus on scaling production and enhancing operational efficiency [15][16] Financial Position and Strategic Outlook - The company maintains a stable cash burn rate and is confident in its ability to execute current plans, having filed over 60 new patent applications in 2025 [17][18] - Increased recognition of Alpha DaRT's relevance in oncology is leading to strategic discussions with potential partners for collaboration [19] - The company anticipates a busy and challenging year in 2026, building on the successes of 2025 and aiming to achieve set goals [20]

Summary of Alpha Tau Medical FY Conference Call Company Overview - **Company**: Alpha Tau Medical (Ticker: DRTS) - **Technology**: Alpha DaRT, a novel method for delivering alpha particles directly into solid tumors, aiming for more efficient local radiation therapy compared to traditional gamma rays or beta particles [5][6] Core Points and Arguments Technology and Applications - **Alpha DaRT Mechanism**: Utilizes a small pin coated with Radium-224 to release isotopes that diffuse into tumors, allowing for a more effective radiation dose with lower activity levels [6] - **Broad Applicability**: Preclinical tests across 20 tumor types have shown positive responses, focusing on high unmet needs like pancreatic and brain tumors [7][8] Clinical Progress - **Skin Cancer Trials**: Ongoing pivotal study for recurrent squamous cell carcinoma (SCC) with near 100% response rates in previous trials. Recruitment completion targeted for Q1 2026 [10][12] - **Pancreatic Cancer Study**: Recent ASCO GI presentations reported over 80% disease control and 20% response rates in a safety and feasibility study, indicating promising results with minimal immune system impact [18][21] - **Glioblastoma (GBM) Trials**: Initial treatments have begun, with successful delivery and 95% tumor coverage in the first patient, highlighting the potential for effective treatment in a challenging cancer type [23][24] Regulatory and Manufacturing Updates - **FDA Submission Strategy**: A modular PMA application allows for rolling submissions, with preclinical data already submitted while awaiting clinical trial results [15][16] - **Manufacturing Expansion**: A new facility in New Hampshire is being developed to meet commercial production needs, with a focus on scaling up capacity for future demand [25][26] Market Strategy - **Go-to-Market Approach**: Plans to build an internal sales force for U.S. markets while exploring partnerships in Canada, Israel, and Asia for commercialization [32][34] Important but Overlooked Content - **Financial Position**: As of Q3, the company had approximately $76 million in cash, with a burn rate of $5-5.5 million per quarter, indicating a solid financial foundation for ongoing operations and trials [38] - **Immunological Effects**: Alpha DaRT appears to preserve immune function while reducing inflammatory markers, suggesting a dual benefit of tumor treatment and immune system support [21][22] Key Deliverables and Milestones for 2026 - Completion of pivotal studies in skin cancer and pancreatic cancer, with data expected later in the year [37] - Ongoing monitoring and updates from the GBM study [37] This summary encapsulates the critical insights from the Alpha Tau Medical FY Conference Call, highlighting the company's innovative approach to cancer treatment, clinical advancements, regulatory strategies, and market positioning.

Summary of Alpha Tau Medical FY Conference Call Company Overview - **Company**: Alpha Tau Medical (NasdaqCM:DRTS) - **Industry**: Healthcare, specifically focused on cancer treatment using alpha particle therapy Core Points and Arguments - **Innovative Treatment**: Alpha Tau has developed a unique treatment for local intratumoral cancer therapy using alpha particles, which is distinct from traditional gamma and beta radiation therapies [2][3] - **Clinical Trials**: The company is currently conducting five approved clinical trials in the U.S. and is expecting significant data points and potential approvals in 2026, including a pivotal trial in skin cancer and studies in pancreatic cancer and glioblastoma [4][5][36] - **Technology Mechanism**: The treatment involves injecting radium-224 into tumors, which decays and releases alpha particles that effectively target cancer cells while minimizing damage to surrounding healthy tissue [7][10][12] - **Safety Profile**: The treatment has shown a mild safety profile with minimal systemic side effects, which is a significant advantage over traditional radiation therapies [14][12] Key Data and Milestones - **Skin Cancer Study**: A pivotal study for recurrent cutaneous squamous cell carcinoma (SCC) has shown a 100% complete response rate in a small pilot study, with plans for FDA submission following data collection [15][16][17] - **Pancreatic Cancer**: Interim data indicates a median overall survival of 7.5 months for untreated patients, significantly higher than the expected 3-3.5 months [28][30] - **GBM Trials**: The first patient for recurrent glioblastoma has been treated, with plans to expand recruitment based on safety data [49][32] Market Opportunity - **Targeted Patient Population**: The company estimates around 64,000 cases of recurrent cutaneous SCC annually in the U.S. and aims to address the 3.5% of cases that recur [18][25] - **Broader Applications**: Alpha Tau is exploring treatments for various cancers, including pancreatic and glioblastoma, which have high unmet medical needs [26][31] Manufacturing and Financials - **Manufacturing Expansion**: Alpha Tau is building a commercial facility in Hudson, New Hampshire, expected to produce enough for 15,000 patients annually, with the first phase completed and licensed [34][35] - **Financial Health**: The company reported approximately $76 million in cash at the end of Q3, with a controlled cash burn rate of $5-$6 million per quarter, allowing for sustained operations through ongoing studies [37][38] Regulatory and Reimbursement Strategy - **FDA Engagement**: Alpha Tau has received breakthrough designation for several indications, facilitating faster regulatory pathways and discussions around reimbursement strategies [47][46] - **Commercial Strategy**: The company plans to establish its own sales force in the U.S. for core indications while exploring partnerships in other markets [60][61] Additional Insights - **Immune Response**: Preliminary findings suggest that the treatment may trigger systemic anti-tumor immunity, enhancing the effectiveness of immunotherapies like Keytruda [19][22] - **Patient-Centric Approach**: The treatment is designed to be minimally invasive, allowing for outpatient procedures and reducing the need for extensive radiation safety measures [12][58] Conclusion - **Transformational Year Ahead**: 2026 is positioned as a pivotal year for Alpha Tau, with multiple regulatory submissions and clinical data expected to drive growth and market presence [35][64]

Core Insights - Alpha Tau Medical Ltd. announced final results from its first-in-human pancreatic cancer study, showing an 81% disease control rate and 87% when excluding the first two patients [1][2] - The study indicates that Alpha DaRT preserves the immune system and has potential anti-inflammatory effects, differing from conventional radiation therapies [1][4] - Alpha DaRT is currently being evaluated in a U.S. multi-center pilot trial in combination with chemotherapy for newly diagnosed pancreatic cancer patients [1][3] Study Results - The trial involved 32 patients with Stage II, III, or IV pancreatic ductal adenocarcinoma (PDAC), achieving a 22% objective response rate (ORR) and an 81% disease control rate (DCR) [2] - Excluding the first two patients, the ORR improved to 23% and the DCR to 87% [2] Immune Response - The immune markers indicated that Alpha DaRT treatment preserved the immune system, with no significant changes in various inflammatory indices post-treatment [4][5] - A significant reduction in IL-6 cytokine levels was observed, suggesting a potential decrease in inflammation [4] Future Trials - The company is pursuing further studies, including the IMPACT trial, to explore Alpha DaRT's efficacy in combination with chemotherapy for patients with unresectable locally advanced or metastatic PDAC [3][6] - The CEO emphasized the importance of pancreatic cancer treatment in the company's strategy and the ongoing recruitment pace for clinical trials [6] Technology Overview - Alpha DaRT utilizes radium-224 for targeted alpha-irradiation of solid tumors, aiming to minimize damage to surrounding healthy tissue [7]

Core Insights - Several biotechnology and pharmaceutical companies experienced significant stock price increases in after-hours trading due to clinical trial updates, regulatory advancements, and investor anticipation for upcoming data releases [1] Company Updates - Alumis Inc. (ALMS) saw a surge of 17.33% to $9.75, gaining $1.44 after announcing that topline data from its Phase 3 ONWARD clinical program for envudeucitinib in moderate-to-severe plaque psoriasis will be reported on January 6, 2026, along with a conference call to discuss the results [2] - Genelux Corp. (GNLX) climbed 10.92% to $3.86, up $0.38, following interim results from ongoing trials evaluating Olvi-Vec in patients with progressive small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) [3] - Bright Minds Biosciences Inc. (DRUG) rose 8.42% to $86.75, gaining $6.74, and announced a conference call on January 6, 2026, to report topline results from its Phase 2 trial of BMB-101 in patients with drug-resistant Absence Seizures [4] - Context Therapeutics Inc. (CNTX) shares increased by 8.36% to $1.68, adding $0.13, despite no specific news released [4] - BioAtla, Inc. (BCAB) gained 3.95% to $0.44, up $0.017, after announcing a special purpose vehicle transaction to advance ozuriftamab vedotin in a Phase 3 study for oropharyngeal squamous cell carcinoma, receiving $5 million in initial funding [5] - Femasys Inc. (FEMY) added 7.09% to $0.6223, up $0.04, with no new updates reported [5] - Acumen Pharmaceuticals, Inc. (ABOS) jumped 11.62% to $2.21, gaining $0.23, also without new corporate updates [6] - Alpha Tau Medical Ltd. (DRTS) rose 5.36% to $5.50, up $0.28, after submitting the first module of its pre-market approval application to the FDA for Alpha DaRT in treating recurrent cutaneous squamous cell carcinoma [7]

Core Insights - Alpha Tau Medical Ltd. has submitted the first module of its pre-market approval (PMA) application to the FDA for its Alpha DaRT therapy aimed at treating recurrent cutaneous squamous cell carcinoma (cSCC) [1][2] - The FDA has granted Alpha Tau a flexible modular submission framework, allowing for streamlined review and feedback as each module is submitted [1][2] - The ReSTART pivotal study, which is currently ongoing, is expected to complete patient recruitment by Q1 2026 [1][2] Company Overview - Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company founded in 2016, focusing on the research, development, and potential commercialization of Alpha DaRT for solid tumors [3] - The Alpha DaRT technology was developed by professors from Tel Aviv University and is designed for targeted alpha-irradiation of tumors [4] Technology Details - Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) utilizes radium-224 sources for intratumoral delivery, aiming to destroy tumors while sparing surrounding healthy tissue [4]